Home Stock Picks Stock Chat Markets Stock Blog Learn to Trade
Stock Newsletters HOT Stock Articles Forex Trading Stock Toolbar Stock Screener Buy Stocks

Solazyme, Inc. (NASDAQ:SZYM) Gets Volatile This Week

[[tagnumber 0]]Solazyme, Inc. (NASDAQ:SZYM) opened the market with a huge gap yesterday while the trading volume reached the highest levels for the past two weeks. SZYM is announcing earnings after market close today and the stock could get even more volatile by the end of the week.[[tagnumber 1]] [[tagnumber 0]][[tagnumber 3]][[tagnumber 1]] [[tagnumber 0]]SZYM opened above the 10 and 20day moving average on Wednesday and volatility was huge as during the session the share price touched the upper Bollinger band. The stock closed then at $3.06 which represents a 15.47% gain from the previous close. Trading exploded as well with over 4.2 million traded shares.[[tagnumber 1]] [[tagnumber 0]]Earlier this week, the company issued a press release that got the attention of traders to increase the hype before the second quarter earnings are announced today. According to the PR, SZYM is starting to commercialize its first surfactant made of renewable microalgae oil. However, the product will be sold by BASF under the trade name Dehyton AO 45 and it will be produced using SZYM technology.[[tagnumber 1]] [[tagnumber 9]][[tagnumber 10]][[tagnumber 1]] [[tagnumber 0]]The statement does not tell any financial details about the conditions under which the two companies will work together, and what will be the benefits of SZYM from this partnership. Hopefully, there will be more data in the second quarter 10Q coming out today.[[tagnumber 1]] [[tagnumber 0]]Technically, SZYM could break above the higher Bollinger band as technical indicators give bullish signals for today, yet longerterm the stock is more likely to lose value. The company is still not making any profits and it has $200 million in convertible debt outstanding which is a considerable risk of dilution for shareholders.[[tagnumber 1]] [[tagnumber 9]] [[tagnumber 1]]


Medical Marijuana Inc (OTCMKTS:MJNA) Surges On Lawsuit News

[[tagnumber 0]][[tagnumber 1]]Medical Marijuana Inc (OTCMKTS:MJNA) has been sliding down the charts, with little exceptions, for quite some time now. This is not a surprise as we have seen other entities involved in the legal cannabis business suffer the same fate.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]And this is not a surprise, considering the fact that the market cap of [[tagnumber 6]]MJNA[[tagnumber 7]] still hovers around the $90 million mark. Meanwhile, the company has not shown any signs that it deserves such a valuation. Its quarterly report for the first quarter of the year listed the following numbers in its balance sheet.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]cash: $634 thousand[[tagnumber 12]]current assets: $5.26 million[[tagnumber 12]]current liabilities: $3.8 million[[tagnumber 12]]quarterly revenues: $3.56 million[[tagnumber 12]]quarterly net loss: $751 thousand[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]And while those numbers are quite dire the company has another card up its sleeve with which it can boost investor confidence. It is the lawsuit filed against multiple companies that allegedly published false allegations about [[tagnumber 6]]MJNA.[[tagnumber 7]][[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Yesterday the company made a press release in which it informed the general public that the AntiSLAPP (strategic lawsuit against public participation) motion has been successfully defeated by [[tagnumber 6]]MJNA[[tagnumber 7]] and the lawsuit can continue.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]This led to an impressive 23.81% gain in price during the session and [[tagnumber 6]]MJNA[[tagnumber 7]] finished with a price of $0.052. The total amount of traded shares was three times the 30 day average and the 15 million that switched hands generated $764 thousand in daily dollar volume.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Still, this doesn’t change the fact that [[tagnumber 6]]MJNA[[tagnumber 7]] is still overpriced, so doing your due diligence and weighing out the risks before putting any money on the line is absolutely crucial.[[tagnumber 2]]


Rainbow Coral Corp (OTCMKTS:RBCC) Drops Further Down The Charts

[[tagnumber 0]][[tagnumber 1]]The first half of the year was rather uneventful for the stock of Rainbow Coral Corp (OTCMKTS:RBCC). The ticker slowly slid below the $1 per share mark and reached 50 cents by the end of June, while being highly illiquid.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Lately, however, the company has gained quite the attention and has risen to impressive price ranges. It reached a high of $7.65 per share in last Friday’s trading, but slid a bit lower for a close of the week at $6.28. The reason for the climb is the claims that the company has a “flagship” product called Naltrexone that is used for the treatment of alcohol and opioid dependence.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Meanwhile, the true story is that [[tagnumber 10]]RBCC[[tagnumber 11]] had no hand in the development of the drug and has merely expressed intent to distribute it throughout the U.S. and Canada. In reality, [[tagnumber 10]]RBCC[[tagnumber 11]] owns a fish store in Venice, Florida and has some pretty horrifying numbers in its 10K report for the period ended March 31, 2015.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 17]] [[tagnumber 18]]cash: $5,180[[tagnumber 19]] [[tagnumber 18]]current assets: $7,414[[tagnumber 19]] [[tagnumber 18]]current liabilities: $453,632[[tagnumber 19]] [[tagnumber 18]]yearly revenues: $128,133[[tagnumber 19]] [[tagnumber 18]]yearly net loss: $990,233[[tagnumber 19]] [[tagnumber 28]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Further concern arises when you look at one of the other reasons for which [[tagnumber 10]]RBCC[[tagnumber 11]] was able to climb to such heights. Back in the end of May the company executed a 1 for 100 reverse split which reduced the share count significantly. In the same time, most of the debt of the company could be turned into shares at a fixed price which ranged from $0.007 to $0.04 per share.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]On June 1, when the company was still hovering around the 50 cent per share mark some noteholders received 6,513,355 shares of common stock at a conversion price of $0.02 per share. A quick look at the OTC marketplace of the company reveals that it had a total of 3 shareholders of record as of July 14, 2015.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]This means that a select group of a few people can make massive profits while retail shareholders buy highly overpriced shares of a fish retailer claiming to be a biotech. This would explain the last two disastrous sessions which pushed [[tagnumber 10]]RBCC[[tagnumber 11]] to $2.85 per share after yesterday’s 21.92% drop.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The profits that can be made by those lucky shareholders are impressively large even at those price levels so we would advise you to do your due diligence and weigh out the risks before putting any money on the line.[[tagnumber 2]]

© 2013 TheHotPennyStocks.com :: Penny Stocks
Home | Privacy | About Penny Stocks | Our Penny Stock List | Penny Stock Trading Basics | Stock Links | Disclaimer
Search Engine Optimization by Port80Media.com